MedTrace Logo

Safety Study of Nebivolol for COPD Patients

NCT01939990 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2016-01-12

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the safety and effectiveness of the study drug Nebivolol, in people who suffer with high blood pressure with Chronic Obstructive Pulmonary Disease (COPD).

Conditions

Interventions

DRUG

Placebo

The placebo looks like the study drug but it does not contain active ingredients.

DRUG

Nebivolol

5 to 10mg per day

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • George Bakris, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01939990 on ClinicalTrials.gov